PT-141 - Sixpex

Approved by the FDA in June 2019, Bremelanotide, or Vyleesi, is designed for premenopausal women experiencing hypoactive sexual desire disorder (HSDD). Unlike other treatments, it targets neuropeptides related to arousal by binding to melanocortin receptors, which play a crucial role in behavioral arousal pathways. Vyleesi’s dopamine release aids in boosting sexual desire, with peak effectiveness generally around 45 minutes after administration, though this timing is still under study. Notably, clinical findings suggest Vyleesi’s ability to ease the psychological distress associated with low sexual desire, presenting a promising option for addressing HSDD with both physical and emotional benefits.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about PT-141 by Sixpex, consult with your doctor or healthcare professional.